|
C9ORF93 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.81943390645756E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.30909727502626E-11 |
| Normal-vs-Stage2 |
9.39910038688652E-10 |
| Normal-vs-Stage3 |
2.30793162359078E-12 |
| Normal-vs-Stage4 |
4.21329637845247E-12 |
| Stage1-vs-Stage2 |
6.448800E-01 |
| Stage1-vs-Stage3 |
1.159390E-01 |
| Stage1-vs-Stage4 |
2.876000E-01 |
| Stage2-vs-Stage3 |
1.380610E-01 |
| Stage2-vs-Stage4 |
2.321200E-01 |
| Stage3-vs-Stage4 |
9.000800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.86000129029662E-12 |
| Normal-vs-AfricanAmerican |
4.05150000000187E-05 |
| Normal-vs-Asian |
1.05030428798614E-11 |
| Caucasian-vs-AfricanAmerican |
8.997800E-02 |
| Caucasian-vs-Asian |
7.588200E-01 |
| AfricanAmerican-vs-Asian |
1.185570E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.18505247018675E-13 |
| Normal-vs-Female |
1.17700293955636E-11 |
| Male-vs-Female |
5.677900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.64761603938769E-12 |
| Normal-vs-Age(41-60Yrs) |
6.03794791942391E-12 |
| Normal-vs-Age(61-80Yrs) |
1.24790178190892E-11 |
| Normal-vs-Age(81-100Yrs) |
5.362400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.794600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.082800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.797600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.152600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.884400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.221800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.356400E-03 |
| Classical-VS-Follicular |
6.538400E-01 |
| Classical-VS-Other |
2.864600E-01 |
| Classical-VS-Normal |
6.29469809609873E-11 |
| Tall-VS-Follicular |
2.183900E-02 |
| Tall-VS-Other |
8.584400E-01 |
| Tall-VS-Normal |
1.47770684577608E-13 |
| Follicular-VS-Other |
4.068600E-01 |
| Follicular-VS-Normal |
7.04150071584309E-11 |
| Other-VS-Normal |
1.57010000001456E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.4928726577732E-12 |
| Normal-vs-N1 |
2.85826917689747E-12 |
| N0-vs-N1 |
2.453400E-01 |
|
|
